Skip to main content
SpringerLink
Log in

Frailty and Safety

The Example of Diabetes

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Frailty is considered a syndrome of decreased reserve and resistance to stressors and is clinically expressed as muscle weakness, poor exercise tolerance, factors related to body composition, sarcopenia and disability. In addition, there is a close relationship between age-related metabolic changes and the occurrence of comorbidities that may in turn lead to frailty.

Even though the downward spiral of frailty is activated more quickly in older persons with type 2 diabetes, it is reversible with appropriate interventions before reaching a high level of severity. The hazard for geriatric patients with type 2 diabetes is that frailty encompasses diverse complications already associated with or caused by diabetes. Frailty is also associated with cognitive impairment, reduced ability to perform activities of daily living and increased expression of inflammatory and coagulation markers that may contribute to the adverse microvascular effects of diabetes. Although glycaemic control remains the main targeting achievement in type 2 diabetes, especially in well-functioning older persons, this is not appropriate for those with frailty. Frail elderly people with type 2 diabetes are a specific group in need of treatment parameters for both initial and maintenance therapy with oral antidiabetic agents. Therefore, the prescription of an antidiabetic agent in such individuals must take into consideration not only the standard goal of lowering hyperglycaemic levels, but also improving the quality of life and life expectancy. The clinical management of this population is currently particularly demanding, requiring special considerations with good medical decision making. Clinical aspects complicating diabetes care in older people include cognitive decline, physical functional decline and frailty. Available oral antidiabetic drugs include insulin secretagogues (meglitinides and sulfonylureas), biguanides (metformin), α-glucosidase inhibitors, thiazolidinediones and inhibitors of glucagon-like peptide 1 (GLP-1) degrading enzyme dipeptidyl peptidase 4. In addition, we will discuss injection treatment with GLP-1 analogues. This review will underline the association between diabetes and some frailty components in old patients and how specific antidiabetic agents may play a specific role in improving outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kim MJ, Rolland Y, Cepeda O, et al. Diabetes mellitus in older men. Aging Male 2006; 9: 139–47

    Article  PubMed  CAS  Google Scholar 

  2. Mazza AD, Morley JE. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc 2007; 8: 489–92

    Article  PubMed  Google Scholar 

  3. Morley JE, Haren MT, Rolland Y, et al. Frailty. Med Clin North Am 2006; 90: 837–47

    Article  PubMed  Google Scholar 

  4. Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: 255–63

    Article  PubMed  Google Scholar 

  5. Morley JE, Kim MJ, Haren MT, et al. Frailty and the aging male. Aging Male 2005; 8: 135–40

    Article  PubMed  CAS  Google Scholar 

  6. Morley JE, Perry HM, Miller DK. Something about frailty. J Gerontol A Biol Sci Med Sci 2002; 57: M698–704

    Article  PubMed  Google Scholar 

  7. ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 364 (9): 818–28

    Article  PubMed  CAS  Google Scholar 

  8. Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypogly-cemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32 (8): 1513–17

    Article  PubMed  CAS  Google Scholar 

  9. Bortz WM II. The physics of frailty JAGS 1993; 41: 1004–8. Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130: 945–50

    Google Scholar 

  10. Abbatecola AM, Paolisso G, Corsonello A, et al. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging 2009; 26 Suppl. 1: 53–62

    Article  PubMed  CAS  Google Scholar 

  11. Fried LP, Tangen CM, Walston J, et al., Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56 (3): M146–56

    Article  PubMed  CAS  Google Scholar 

  12. Abbatecola AM, Rizzo MR, Barbieri M, et al. Post-prandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67 (2): 235–40

    Article  PubMed  CAS  Google Scholar 

  13. Volpato S, Ferrucci L, Blaum C, et al. Progression of lower-extremity disability in older women with diabetes: the Women’s Health and Aging Study. Diabetes Care 2003; 1: 70–5

    Article  Google Scholar 

  14. Vanitallie TB. Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. Metabolism 2003; 52 (10 Suppl. 2): 22–6

    Article  PubMed  Google Scholar 

  15. Evans WJ, Paolisso G, Abbatecola AM, et al. Frailty and muscle metabolism dysregulation in the elderly. Biogerontology 2010; 11 (5): 527–36

    Article  PubMed  CAS  Google Scholar 

  16. Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006; 55 (6): 1813–18

    Article  PubMed  CAS  Google Scholar 

  17. Franceschi C, Bonafe M, Valensin S, et al. Inflammaging: An evoluzinary perspective on immunosenescence. Ann NY Acad Sci 2000; 908: 244–54

    Article  PubMed  CAS  Google Scholar 

  18. Abbatecola AM, Ferrucci L, Grella R, et al. Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc 2004; 52 (3): 399–404

    Article  PubMed  Google Scholar 

  19. Spazzafumo L, Olivieri F, Abbatecola AM, et al. Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes. Age (Dordr) Epub 2011

    Google Scholar 

  20. Jones SA, Horiuchi S, Topley N, et al. The soluble inter-leukin 6 receptor: mechanisms of production and implication in disease. FASEB J 2001; 15: 43–58

    Article  PubMed  CAS  Google Scholar 

  21. Kawazoe Y, Naka T, Fujimoto M, et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor (SSI-1)/Suppressor of Cytokine Signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 2001; 193: 263–9

    Article  PubMed  CAS  Google Scholar 

  22. Krebs DL, Hilton DJ. SOCS: Physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813–19

    PubMed  CAS  Google Scholar 

  23. Cappola AR, Xue QL, Ferrucci L, et al. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88 (5): 2019–25

    Article  PubMed  CAS  Google Scholar 

  24. Joya-Galeana J, Fernandez M, Cervera A, et al. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes Metab Res Rev 2011; 27 (4): 373–82

    Article  PubMed  CAS  Google Scholar 

  25. Perez A, Jacks R, Arora V, et al. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens (Greenwich) 2010; 12 (12): 973–82

    Article  CAS  Google Scholar 

  26. Ferrucci L, Cavazzini C, Corsi A, et al. Biomarkers of frailty in older persons. J Endocrinol Invest 2002; 25: 10–15

    PubMed  CAS  Google Scholar 

  27. Laakso M, Edelman SV, Brechtel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85 (6): 1844–52

    Article  PubMed  CAS  Google Scholar 

  28. Abbatecola AM, Chiodini P, Gallo C, et al., Health ABC study. Pulse wave velocity is associated with muscle mass decline: Health ABC study. Age (Dordr) 2012; 34 (2): 469–78

    Article  Google Scholar 

  29. Sinclair AJ, Paolisso G, Castro M, et al., European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011; 37 Suppl. 3: S27–38

    Article  PubMed  Google Scholar 

  30. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older persons with diabetes. J Am Geriatr Soc 2003; 51 (suppl guidelines): S265–80

    Article  PubMed  Google Scholar 

  31. Cayea D, Boyd C, Durso SC. Individualising therapy for older adults with diabetes mellitus. Drugs&Aging 2007; 24 (10): 851–63

    CAS  Google Scholar 

  32. Patel A, MacMahon S, Chalmers J, et al., ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560–72

    Article  PubMed  CAS  Google Scholar 

  33. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003; 2 (6): 401–14

    Article  PubMed  CAS  Google Scholar 

  34. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334 (9): 574–9

    Article  PubMed  CAS  Google Scholar 

  35. Radziuk J, Bailey CJ, Wiernsperger NF, et al. Metformin and its liver targets in the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3 (2): 151–69

    Article  PubMed  CAS  Google Scholar 

  36. American diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 Suppl. 1: S11–61

    Article  Google Scholar 

  37. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193–203

    Article  PubMed  CAS  Google Scholar 

  38. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244–8

    Article  PubMed  CAS  Google Scholar 

  39. Chapman IM. Anorexia of aging. Clin Geriat Med 2007; 23 (4): 735–56

    Article  Google Scholar 

  40. Tamura Y, Araki A, Chiba Y, et al. Postprandial reactive hypoglycemia in an oldest-old patient effectively treated with low-dose acarbose. Endocr J 2006; 53 (6): 767–71

    Article  PubMed  CAS  Google Scholar 

  41. Pratley RE, Gilbert M. Clinical management of elderly patients with type 2 diabetes mellitus. Postgrad Med 2012; 124 (1): 133–43

    Article  PubMed  Google Scholar 

  42. Erdmann E, Charbonnel B, Wilcox RG, et al. PROactive investigators Pioglitazone use and heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30 (11): 2773–8

    Article  PubMed  CAS  Google Scholar 

  43. Kahn SE, Zinman B, Lachin JM, et al. Diabetes Outcome Progression Trial (ADOPT) Study Group Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31 (5): 845–51

    Article  PubMed  CAS  Google Scholar 

  44. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180 (1): 32–9

    PubMed  Google Scholar 

  45. Linnebjerg H, Kothare PA, Seger M, et al. Exenatide-pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥75 years of age with type 2 diabetes. Int J Clin Pharmacol Ther 2011; 49 (2): 99–108

    PubMed  CAS  Google Scholar 

  46. Buse JB, Rosenstock J, Sesti G, et al., LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374 (9683): 39–47

    Article  PubMed  CAS  Google Scholar 

  47. Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20 (4): 224–35

    Article  PubMed  CAS  Google Scholar 

  48. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97 (5): 1615–22

    Article  PubMed  CAS  Google Scholar 

  49. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011; 27 (5): 1049–58

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Direction, Italian National Research Center on Aging (INRCA), Ancona, Italy

    Angela M. Abbatecola & Fabrizia Lattanzio

  2. Department of Molecular Pathology and Innovative Therapies, Università Politecnica delle Marche, Ancona, Italy

    Fabiola Olivieri

  3. Center of Clinical Pathology and Innovative Therapy, INRCA, Ancona, Italy

    Fabiola Olivieri

  4. Unit of Geriatric Pharmacoepidemiology, Research Hospital of Cosenza, Italian National Research Center on Aging (I.N.R.C.A), Cosenza, Italy

    Andrea Corsonello

  5. Unit of Endocrinology, Research Hospital of Rome, Italian National Research Center on Aging (INRCA), Rome, Italy

    Felice Strollo

  6. Unit of Pulmonary Rehabilitation, Research Hospital of Casatenovo, Italian National Research Center on Aging (INRCA), Casatenovo, Italy

    Alessia Fumagalli

Authors
  1. Angela M. Abbatecola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabiola Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Corsonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felice Strollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessia Fumagalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fabrizia Lattanzio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela M. Abbatecola.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbatecola, A.M., Olivieri, F., Corsonello, A. et al. Frailty and Safety. Drug Saf 35 (Suppl 1), 63–71 (2012). https://doi.org/10.1007/BF03319104

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03319104

Keywords

Search

Navigation